The United States Food and Drug Administration has granted Marshall Edwards, Inc. an investigative new drug (IND) indication for triphendiol (NV-196).

Triphendiol is a chemosensitizing agent that is thought to depolarize mitochrondria and downregulate XIAP. It has also demonstrated broad cytostatic and cytotoxic properties against human cancer cells in vitro.

The IND indication is for triphendiol to be used in combination with Gemzar® (gemcitabine) for the treatment of unresectable, locally advanced, or metastatic pancreatic and bile duct cancers. The IND will enable a Phase IB study of triphendiol to proceed.

Recommended Articles

Image placeholder title

Tisotumab Vedotin – Promising in Advanced Cervical Cancer

Novel precision cancer medicine promising for treatment of advanced ovarian cancer.

Image placeholder title

Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer

Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.

Ovarian News Updates

Precision Antibody-drug conjugate promising in Ovarian Cancer

Learn about the STRO-002 Antibody-drug conjugate in Ovarian Cancer